Inadvertent intrathecal administration of vincristine

Community Oncology

Volumn 4, Issue 1, 2007, Pages 45-46

  Lagman, Jennifer L ^a,b   Tigue, Cara C ^b,c   Trifilio, Steven M ^a   Belknap, Steven ^b   Buffie, Charlie G ^b,c   Bennett, Charles L ^b,c,d  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; AUTONOMIC DYSFUNCTION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; COMA; DIAPHRAGM PARALYSIS; DRUG INFORMATION; DRUG LABELING; ENCEPHALITIS; HUMAN; INTERPERSONAL COMMUNICATION; MEDICATION ERROR; MENINGITIS; MOTOR DYSFUNCTION; MYELOENCEPHALOPATHY; RESPIRATORY FAILURE; SHORT SURVEY; TREATMENT FAILURE;

EID: 33847790516     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70022-5     Document Type: Short Survey

References (4)

1. Alcaraz A, Rey C, Concha A, Medina A. Intrathecal vincristine: fatal myeloencephalopathy despite cerebrospinal fluid perfusion. J Toxicol Clin Toxicol 2002;40:557-561.
2. Schochet SS Jr, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol 1968;27:645-658.
3. Gilbar PJ, Carrington CV. Preventing intrathecal administration of vincristine. Med J Aust 2004;181:464.
4. Joint Commission on Accreditation of Health Care Organizations. Preventing vincristine administration errors. Sentinel Event Alert 2005; Jul 14:1-3.